PNMA8A

Across TCGA pan-cancer cohorts, PNMA8A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PNMA8A data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher PNMA8A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PNMA8A expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

GBM, LSCC, and PDAC are the cancer types where PNMA8A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Quartile	All	0.801	0.355	<.001	21	view →
LSCC	DFS	Median	II,III,IV	0.889	0.449	.026	4	view →
PDAC	DFS	Median	All	0.702	0.256	.026	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PNMA8A–GBM (OS)

Open the GBM breakdown →